Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CH7Z
|
|||
| Drug Name |
PMID28870136-Compound-44
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N4O2
|
|||
| Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=CC=C3
|
|||
| InChI |
1S/C17H20N4O2/c1-3-10-20-15-13(16(22)21(11-4-2)17(20)23)18-14(19-15)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,18,19)
|
|||
| InChIKey |
CLIGSMOZKDCDRZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 85872-53-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:107631
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ecto-5'-nucleotidase (CD73) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Ecto-5'-nucleotidase (CD73) | Target's Patent Info | [1] | |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Adenosine nucleotides degradation | ||||
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Nicotinate and nicotinamide metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Purine metabolism | |||
| Pyrimidine Metabolism | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Purine catabolism | |||
| WikiPathways | Differentiation Pathway | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Metabolism of nucleotides | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.